I’ll let you in on a little secret: I’m not supposed to attend the health care conference in Boston organized by the investment bank Cowen each March. Technically, it’s a media-free event.

But as long as I behave myself and don’t live-tweet from the sessions, Cowen tolerates my presence. I’m grateful because the conference’s unique setup — investors and doctor-specialists critique approved and experimental drugs across nearly two dozen disease areas — offers a helpful sentiment check on biotech and pharma companies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy